New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1946 - 1960
BACKGROUND Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two...
MEDICINE, GENERAL & INTERNAL | INFECTIONS | ARTICLE | INFLAMMATORY-BOWEL-DISEASE | ADALIMUMAB | EFFICACY | SAFETY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | INFLIXIMAB | Humans | Middle Aged | Induction Chemotherapy | Male | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Ustekinumab - pharmacokinetics | Crohn Disease - drug therapy | Ustekinumab - immunology | Adult | Female | Maintenance Chemotherapy | Infusions, Intravenous
MEDICINE, GENERAL & INTERNAL | INFECTIONS | ARTICLE | INFLAMMATORY-BOWEL-DISEASE | ADALIMUMAB | EFFICACY | SAFETY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | INFLIXIMAB | Humans | Middle Aged | Induction Chemotherapy | Male | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Ustekinumab - pharmacokinetics | Crohn Disease - drug therapy | Ustekinumab - immunology | Adult | Female | Maintenance Chemotherapy | Infusions, Intravenous
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1568 - 1578
BACKGROUND & AIMS: Most patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after resection. We...
Anti-TNF | Inflammatory Bowel Disease | PREVENT | CDAI | ILEAL RESECTION | INTESTINAL RESECTION | RANDOMIZED CONTROLLED-TRIAL | DEEP REMISSION | THERAPY | POSTSURGICAL RECURRENCE | PREVENT POSTOPERATIVE RECURRENCE | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ACTIVITY INDEX | GASTROENTEROLOGY & HEPATOLOGY | Recurrence | Ileum - pathology | Double-Blind Method | Colon - pathology | Humans | Middle Aged | Crohn Disease - surgery | Gastrointestinal Agents - administration & dosage | Postoperative Period | Male | Treatment Outcome | Secondary Prevention - methods | Colon - surgery | Infliximab - administration & dosage | Crohn Disease - pathology | Colonoscopy | Crohn Disease - drug therapy | Ileum - surgery | Adult | Female | Colectomy - adverse effects | Health care industry | Relapse | Infliximab | Surgery | Diseases
Anti-TNF | Inflammatory Bowel Disease | PREVENT | CDAI | ILEAL RESECTION | INTESTINAL RESECTION | RANDOMIZED CONTROLLED-TRIAL | DEEP REMISSION | THERAPY | POSTSURGICAL RECURRENCE | PREVENT POSTOPERATIVE RECURRENCE | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ACTIVITY INDEX | GASTROENTEROLOGY & HEPATOLOGY | Recurrence | Ileum - pathology | Double-Blind Method | Colon - pathology | Humans | Middle Aged | Crohn Disease - surgery | Gastrointestinal Agents - administration & dosage | Postoperative Period | Male | Treatment Outcome | Secondary Prevention - methods | Colon - surgery | Infliximab - administration & dosage | Crohn Disease - pathology | Colonoscopy | Crohn Disease - drug therapy | Ileum - surgery | Adult | Female | Colectomy - adverse effects | Health care industry | Relapse | Infliximab | Surgery | Diseases
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2018, Volume 47, Issue 7, pp. 940 - 950
Background: The validity of the eosinophilic oesophagitis (EoE) histologic scoring system (EoEHSS) has been demonstrated, but only preliminary reliability data...
DYSPHAGIA | DIAGNOSIS | MANAGEMENT | ELEMENTAL DIET | DOUBLE-BLIND | ADULTS | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | CHILDREN | Medical research | Component reliability | Epithelial cells | Leukocytes (eosinophilic) | Correlation coefficients | Clinical trials | Benchmarks | Lamina propria | Scoring | Estimates | Patients | Reliability analysis | Eosinophils
DYSPHAGIA | DIAGNOSIS | MANAGEMENT | ELEMENTAL DIET | DOUBLE-BLIND | ADULTS | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | CHILDREN | Medical research | Component reliability | Epithelial cells | Leukocytes (eosinophilic) | Correlation coefficients | Clinical trials | Benchmarks | Lamina propria | Scoring | Estimates | Patients | Reliability analysis | Eosinophils
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Summary Background Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | EUROQOL | SCORE | VALIDATION | QUALITY-OF-LIFE | INDEX | INFLIXIMAB | SEVERITY | HEALTH SURVEY | SF-36 | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Immunosuppression - methods | Humans | Mercaptopurine - administration & dosage | Male | Treatment Outcome | Methotrexate - therapeutic use | Antimetabolites - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antimetabolites - administration & dosage | Crohn Disease - therapy | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Mercaptopurine - therapeutic use | Adult | Female | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Gastrointestinal diseases | Immunotherapy | Algorithms | Surgery | Mortality | Gastroenterology | Drug therapy | Crohns disease | Quality of life
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | EUROQOL | SCORE | VALIDATION | QUALITY-OF-LIFE | INDEX | INFLIXIMAB | SEVERITY | HEALTH SURVEY | SF-36 | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Immunosuppression - methods | Humans | Mercaptopurine - administration & dosage | Male | Treatment Outcome | Methotrexate - therapeutic use | Antimetabolites - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antimetabolites - administration & dosage | Crohn Disease - therapy | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Mercaptopurine - therapeutic use | Adult | Female | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Gastrointestinal diseases | Immunotherapy | Algorithms | Surgery | Mortality | Gastroenterology | Drug therapy | Crohns disease | Quality of life
Journal Article
American journal of gastroenterology, ISSN 0002-9270, 2015, Volume 110, Issue 9, pp. 1324 - 1338
The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory...
C-REACTIVE PROTEIN | EVIDENCE-BASED CONSENSUS | FORM HEALTH SURVEY | COMPUTED-TOMOGRAPHY ENTEROGRAPHY | NECROSIS-FACTOR-ALPHA | QUALITY-OF-LIFE | ACTIVE ULCERATIVE-COLITIS | RANDOMIZED CONTROLLED-TRIAL | GASTROENTEROLOGY & HEPATOLOGY | POST-HOC ANALYSIS | PATIENT-REPORTED OUTCOMES | Remission Induction - methods | Disease Management | Humans | Inflammatory Bowel Diseases - therapy | Practice Guidelines as Topic | Life Sciences
C-REACTIVE PROTEIN | EVIDENCE-BASED CONSENSUS | FORM HEALTH SURVEY | COMPUTED-TOMOGRAPHY ENTEROGRAPHY | NECROSIS-FACTOR-ALPHA | QUALITY-OF-LIFE | ACTIVE ULCERATIVE-COLITIS | RANDOMIZED CONTROLLED-TRIAL | GASTROENTEROLOGY & HEPATOLOGY | POST-HOC ANALYSIS | PATIENT-REPORTED OUTCOMES | Remission Induction - methods | Disease Management | Humans | Inflammatory Bowel Diseases - therapy | Practice Guidelines as Topic | Life Sciences
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2017, Volume 45, Issue 8, pp. 1128 - 1134
Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation...
MAINTENANCE | IMMUNOGENICITY | MONOTHERAPY | CROHNS-DISEASE | COMBINATION THERAPY | ULCERATIVE-COLITIS | AZATHIOPRINE | PHARMACOLOGY & PHARMACY | SERUM | TROUGH LEVELS | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Inflammatory Bowel Diseases - drug therapy | Adalimumab - immunology | Humans | Inflammatory Bowel Diseases - immunology | Middle Aged | Immunologic Factors - administration & dosage | Male | Inflammatory Bowel Diseases - blood | Methotrexate - therapeutic use | Infliximab - immunology | Infliximab - administration & dosage | Antibodies, Monoclonal - blood | Young Adult | Adalimumab - administration & dosage | Adult | Female | Aged | Retrospective Studies | Drug Therapy, Combination | Adjuvants, Immunologic - therapeutic use | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Viral antibodies | Care and treatment | Infliximab | Gastrointestinal diseases | Antibodies | Methotrexate | Biopharmaceutics | Inflammatory bowel diseases | Immunoglobulins | Immunomodulation | Tumor necrosis factor-α | Dosage | Patients | Switching | Inflammatory bowel disease | Immunogenicity | Intestine | Monoclonal antibodies | Measurement methods | Tumor necrosis factor-TNF | Immunomodulators | Tumors
MAINTENANCE | IMMUNOGENICITY | MONOTHERAPY | CROHNS-DISEASE | COMBINATION THERAPY | ULCERATIVE-COLITIS | AZATHIOPRINE | PHARMACOLOGY & PHARMACY | SERUM | TROUGH LEVELS | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Inflammatory Bowel Diseases - drug therapy | Adalimumab - immunology | Humans | Inflammatory Bowel Diseases - immunology | Middle Aged | Immunologic Factors - administration & dosage | Male | Inflammatory Bowel Diseases - blood | Methotrexate - therapeutic use | Infliximab - immunology | Infliximab - administration & dosage | Antibodies, Monoclonal - blood | Young Adult | Adalimumab - administration & dosage | Adult | Female | Aged | Retrospective Studies | Drug Therapy, Combination | Adjuvants, Immunologic - therapeutic use | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Viral antibodies | Care and treatment | Infliximab | Gastrointestinal diseases | Antibodies | Methotrexate | Biopharmaceutics | Inflammatory bowel diseases | Immunoglobulins | Immunomodulation | Tumor necrosis factor-α | Dosage | Patients | Switching | Inflammatory bowel disease | Immunogenicity | Intestine | Monoclonal antibodies | Measurement methods | Tumor necrosis factor-TNF | Immunomodulators | Tumors
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 03/2017, Volume 45, Issue 5, pp. 617 - 630
Summary Background Although optimal medical management of acute severe ulcerative colitis (UC) is ill‐defined, infliximab has become a standard of care....
TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | EVIDENCE-BASED CONSENSUS | INDUCTION THERAPY | CROHNS-DISEASE | SERUM INFLIXIMAB | EARLY COLECTOMY | FECAL CALPROTECTIN LEVELS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | RESCUE THERAPY | Antibodies, Monoclonal - administration & dosage | Humans | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Colectomy | Colitis, Ulcerative - drug therapy | Infliximab - administration & dosage | Randomized Controlled Trials as Topic | Infliximab | Ulcerative colitis | Leakage | Dosing | Inflammatory bowel diseases | Clinical trials | Pharmacology | Tumor necrosis factor-α | Patients | Optimization | Amplification | Inflammatory bowel disease | Randomization | Monoclonal antibodies | Colon | Pharmacokinetics | Cross sections
TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | EVIDENCE-BASED CONSENSUS | INDUCTION THERAPY | CROHNS-DISEASE | SERUM INFLIXIMAB | EARLY COLECTOMY | FECAL CALPROTECTIN LEVELS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | RESCUE THERAPY | Antibodies, Monoclonal - administration & dosage | Humans | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Colectomy | Colitis, Ulcerative - drug therapy | Infliximab - administration & dosage | Randomized Controlled Trials as Topic | Infliximab | Ulcerative colitis | Leakage | Dosing | Inflammatory bowel diseases | Clinical trials | Pharmacology | Tumor necrosis factor-α | Patients | Optimization | Amplification | Inflammatory bowel disease | Randomization | Monoclonal antibodies | Colon | Pharmacokinetics | Cross sections
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 1, pp. 110 - 118.e4
Background & Aims Several case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). We assessed the efficacy...
Gastroenterology and Hepatology | Randomized Controlled Trial | Fecal Microbiota Transplantation | Inflammatory Bowel Disease | MILD | INFLAMMATORY-BOWEL-DISEASE | THERAPY | INTESTINAL MICROBIOTA | PHYLOGENETIC MICROARRAY | BACTERIAL | GASTROENTEROLOGY & HEPATOLOGY | REMISSION | Biological Therapy - methods | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Remission Induction | Feces - microbiology | Microbiota | Intubation, Gastrointestinal - utilization | Colitis, Ulcerative - therapy | Adult | Female | Aged | Medicine, Experimental | Medical research | Care and treatment | Microbiota (Symbiotic organisms) | Ulcerative colitis | Microbiological Laboratory | Microbiologie | Microbiology | VLAG | Laboratorium voor Microbiologie
Gastroenterology and Hepatology | Randomized Controlled Trial | Fecal Microbiota Transplantation | Inflammatory Bowel Disease | MILD | INFLAMMATORY-BOWEL-DISEASE | THERAPY | INTESTINAL MICROBIOTA | PHYLOGENETIC MICROARRAY | BACTERIAL | GASTROENTEROLOGY & HEPATOLOGY | REMISSION | Biological Therapy - methods | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Remission Induction | Feces - microbiology | Microbiota | Intubation, Gastrointestinal - utilization | Colitis, Ulcerative - therapy | Adult | Female | Aged | Medicine, Experimental | Medical research | Care and treatment | Microbiota (Symbiotic organisms) | Ulcerative colitis | Microbiological Laboratory | Microbiologie | Microbiology | VLAG | Laboratorium voor Microbiologie
Journal Article
Alimentary pharmacology & therapeutics, ISSN 0269-2813, 2017, Volume 46, Issue 5, pp. 516 - 528
Magnetic resonance imaging (MRI) is the gold standard for assessment of perianal fistulising Crohn's disease (CD). The Van Assche index is the most commonly...
COMPLEX PERIANAL FISTULAS | MRI | GUIDELINES | CONSENSUS | CLASSIFICATION | PHARMACOLOGY & PHARMACY | RELIABILITY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | Severity of Illness Index | Crohn Disease - diagnostic imaging | Reproducibility of Results | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Male | Consensus | Young Adult | Crohn Disease - pathology | Adult | Female | Aged | Magnetic resonance imaging | Conventions | Component reliability | Nuclear magnetic resonance--NMR | Correlation coefficients | Fistulae | Scoring | Crohn's disease | Crohns disease | Confidence intervals | Rectum | Reliability analysis | Resonance
COMPLEX PERIANAL FISTULAS | MRI | GUIDELINES | CONSENSUS | CLASSIFICATION | PHARMACOLOGY & PHARMACY | RELIABILITY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | Severity of Illness Index | Crohn Disease - diagnostic imaging | Reproducibility of Results | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Male | Consensus | Young Adult | Crohn Disease - pathology | Adult | Female | Aged | Magnetic resonance imaging | Conventions | Component reliability | Nuclear magnetic resonance--NMR | Correlation coefficients | Fistulae | Scoring | Crohn's disease | Crohns disease | Confidence intervals | Rectum | Reliability analysis | Resonance
Journal Article